The primary objective of CONVERGE PAS is to evaluate clinical outcomes (peri-procedural and long-term) in a cohort of patients treated during commercial use of the EPi-Sense® Guided Coagulation System or EPi-Sense ST™ Coagulation System to treat symptomatic long-standing persistent atrial fibrillation (AF) patients who are refractory or intolerant to at least one Class I and/or III AAD.
Chronic Atrial Fibrillation
The primary objective of CONVERGE PAS is to evaluate clinical outcomes (peri-procedural and long-term) in a cohort of patients treated during commercial use of the EPi-Sense® Guided Coagulation System or EPi-Sense ST™ Coagulation System to treat symptomatic long-standing persistent atrial fibrillation (AF) patients who are refractory or intolerant to at least one Class I and/or III AAD.
CONVERGE Post-Approval Study (PAS)
-
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States, 92663
Baycare Health Systems, Clearwater, Florida, United States, 33759
Emory Saint Joseph Hopsital, Atlanta, Georgia, United States, 30322
MedStar Union Memorial Hospital, Baltimore, Maryland, United States, 21218
Southcoast Hospitals Group, New Bedford, Massachusetts, United States, 02740
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States, 27157
Bon Secours, Midlothian, Virginia, United States, 23114
Virginia Mason Medical Center, Seattle, Washington, United States, 98101
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to 80 Years
ALL
No
AtriCure, Inc.,
2025-12-31